US 11,939,396 B2
Anti-tryptase antibodies, compositions thereof, and uses thereof
Xiaocheng Chen, Foster City, CA (US); Mark Dennis, San Carlos, CA (US); Janet Jackman, Half Moon Bay, CA (US); James T. Koerber, San Francisco, CA (US); Mason Lu, Houston, TX (US); Henry R. Maun, San Francisco, CA (US); Kathila Rajapaksa, San Francisco, CA (US); Saroja Ramanujan, San Mateo, CA (US); Tracy Staton, Stanford, CA (US); Lawren Wu, Foster City, CA (US); and Tangsheng Yi, Belmont, CA (US)
Assigned to Genentech, Inc., South San Francisco, CA (US)
Filed by Genentech, Inc., South San Francisco, CA (US)
Filed on Jun. 30, 2020, as Appl. No. 16/916,822.
Application 16/916,822 is a division of application No. 15/893,238, filed on Feb. 9, 2018, granted, now 10,738,131.
Claims priority of provisional application 62/457,722, filed on Feb. 10, 2017.
Prior Publication US 2020/0325248 A1, Oct. 15, 2020
Int. Cl. C07K 16/40 (2006.01); A61K 39/395 (2006.01); C07K 16/24 (2006.01); A61K 39/00 (2006.01); A61K 45/06 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01); A61K 47/22 (2006.01); A61K 47/26 (2006.01)
CPC C07K 16/40 (2013.01) [A61K 39/3955 (2013.01); A61K 39/39591 (2013.01); C07K 16/244 (2013.01); C12Y 304/21059 (2013.01); A61K 2039/505 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/183 (2013.01); A61K 47/22 (2013.01); A61K 47/26 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/34 (2013.01); C07K 2317/40 (2013.01); C07K 2317/55 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/567 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01); C07K 2317/94 (2013.01)] 33 Claims
 
1. A method of treating asthma in a human subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of an isolated antibody that binds to human tryptase beta 1, or an antigen-binding fragment thereof, wherein the antibody comprises the following six hypervariable regions (HVRs):
(a) an HVR-H1 comprising the amino acid sequence of DYGMV (SEQ ID NO: 7);
(b) an HVR-H2 comprising the amino acid sequence of FISSGSSTVYYADTMKG (SEQ ID NO: 2);
(c) an HVR-H3 comprising the amino acid sequence of RNYDDWYFDV (SEQ ID NO: 8);
(d) an HVR-L1 comprising the amino acid sequence of SASSSVTYMY (SEQ ID NO: 4);
(e) an HVR-L2 comprising the amino acid sequence of RTSDLAS (SEQ ID NO: 5); and
(f) an HVR-L3 comprising the amino acid sequence of QHYHSYPLT (SEQ ID NO: 6).